Vertex Pharmaceuticals (VRTX) FCF Margin (2009 - 2026)

Vertex Pharmaceuticals' FCF Margin history runs 18 years deep, the most recent figure standing at 43.35% for Q1 2026.

• In Q1 2026, FCF Margin rose 1525.0% year-over-year to 43.35%; the TTM figure through Mar 2026 stood at 30.37% (up 4163.0% YoY), while the FY2025 annual figure was 26.61%, up 3378.0% from the prior year.
• FCF Margin was 43.35% for Q1 2026 at Vertex Pharmaceuticals, up from 10.93% in the prior quarter.
• In the past five years, FCF Margin ranged from a high of 49.47% in Q2 2022 to a low of 144.49% in Q2 2024.
• Historically, FCF Margin has averaged 25.16% across 5 years, with a median of 38.61% in 2022.
• The sharpest annual moves came in 2024 and 2025: FCF Margin sank 18760 bps in 2024, then surged 17577 bps in 2025.
• A 5-year view of FCF Margin shows it stood at 45.37% in 2022, then sank by 85 bps to 7.01% in 2023, then jumped by 141 bps to 16.9% in 2024, then plunged by 35 bps to 10.93% in 2025, then surged by 297 bps to 43.35% in 2026.
• The last three FCF Margin figures came in at 43.35% (Q1 2026), 10.93% (Q4 2025), and 37.04% (Q3 2025), per Business Quant data.